All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

cefazolin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	530	25953-19-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefazolin cefazolin sodium cefamezin cefaprim cefazoline cephamezine cephazolin cephazoline cefazolin sodium salt	A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Molecular weight: 454.50 Formula: C14H14N8O4S3 CLOGP: -0.64 LIPINSKI: 1 HAC: 12 HDO: 2 TPSA: 156.09 ALOGS: -2.97 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
3	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	33 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	80 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	146.75 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.89 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.18 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 4, 1973	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	434.83	13.36	176	14100	19979	50570869
Anaphylactic reaction	218.04	13.36	154	14122	53901	50536947
Arthrodesis	155.65	13.36	48	14228	2437	50588411
Hypotension	152.99	13.36	253	14023	235216	50355632
Postoperative wound infection	119.95	13.36	55	14221	8420	50582428
Acute generalised exanthematous pustulosis	107.98	13.36	52	14224	8886	50581962
Fatigue	82.60	13.36	49	14227	707552	49883296
Bronchospasm	73.30	13.36	48	14228	14806	50576042
Exposure during pregnancy	72.97	13.36	126	14150	120889	50469959
Drug hypersensitivity	63.93	13.36	185	14091	250825	50340023
Vitamin K deficiency	62.50	13.36	16	14260	407	50590441
Erythema	61.79	13.36	131	14145	146283	50444565
Urticaria	60.65	13.36	121	14155	129440	50461408
Shoulder arthroplasty	60.43	13.36	26	14250	3422	50587426
Amniotic cavity infection	58.46	13.36	19	14257	1144	50589704
Limb operation	57.75	13.36	25	14251	3339	50587509
Type I hypersensitivity	55.41	13.36	22	14254	2363	50588485
Cardiac arrest	52.89	13.36	89	14187	83562	50507286
Premature baby	51.18	13.36	42	14234	18295	50572553
Tachycardia	50.10	13.36	96	14180	99667	50491181
Renal failure	49.18	13.36	99	14177	106534	50484314
Drug-induced liver injury	44.64	13.36	47	14229	28048	50562800
Anaesthetic complication	43.86	13.36	17	14259	1713	50589135
Recurrence of neuromuscular blockade	42.65	13.36	9	14267	94	50590754
Renal injury	40.47	13.36	27	14249	8584	50582264
Kounis syndrome	38.74	13.36	14	14262	1161	50589687
Blood pressure decreased	38.72	13.36	62	14214	55847	50535001
Hypoprothrombinaemia	38.60	13.36	10	14266	267	50590581
Toxic epidermal necrolysis	38.60	13.36	38	14238	20954	50569894
Vascular purpura	38.30	13.36	14	14262	1200	50589648
Rash	38.27	13.36	232	14044	437239	50153609
Alopecia	36.23	13.36	12	14264	245035	50345813
Fear	35.81	13.36	31	14245	14518	50576330
Acute hepatic failure	35.78	13.36	32	14244	15645	50575203
Anhedonia	35.72	13.36	26	14250	9498	50581350
Drug intolerance	35.57	13.36	9	14267	219095	50371753
Purpura senile	32.20	13.36	10	14266	519	50590329
Tarsal tunnel syndrome	32.02	13.36	10	14266	529	50590319
Unevaluable event	31.78	13.36	51	14225	46015	50544833
Product dose omission issue	30.91	13.36	7	14269	183831	50407017
Injury	30.83	13.36	52	14224	48873	50541975
Thrombotic microangiopathy	30.72	13.36	23	14253	8768	50582080
Pseudomembranous colitis	30.03	13.36	15	14261	2770	50588078
Disseminated intravascular coagulation	29.62	13.36	30	14246	17105	50573743
Post procedural complication	29.00	13.36	28	14248	15076	50575772
Headache	28.53	13.36	63	14213	506472	50084376
Multiple organ dysfunction syndrome	28.45	13.36	51	14225	50286	50540562
Death	27.27	13.36	31	14245	325348	50265500
Coagulopathy	26.70	13.36	29	14247	17915	50572933
Hepatic function abnormal	26.50	13.36	39	14237	32642	50558206
Weight increased	26.34	13.36	12	14264	201879	50388969
Foetal anaemia	26.15	13.36	5	14271	30	50590818
Isoimmune haemolytic disease	26.01	13.36	5	14271	31	50590817
Sinusitis	25.82	13.36	8	14268	170550	50420298
Toxic skin eruption	25.74	13.36	23	14253	11228	50579620
Peripheral swelling	25.70	13.36	13	14263	205923	50384925
Hyperthermia malignant	25.10	13.36	9	14267	730	50590118
Premature delivery	24.85	13.36	32	14244	23631	50567217
Systemic lupus erythematosus	24.36	13.36	5	14271	140617	50450231
Post procedural haematoma	24.04	13.36	10	14266	1210	50589638
Pain in extremity	23.96	13.36	25	14251	272840	50318008
Tonic clonic movements	23.91	13.36	10	14266	1227	50589621
Heparin-induced thrombocytopenia	22.50	13.36	14	14262	3951	50586897
Maternal exposure during delivery	22.40	13.36	9	14267	997	50589851
Resorption bone increased	22.35	13.36	9	14267	1002	50589846
Implant site haematoma	22.09	13.36	5	14271	74	50590774
Malaise	22.09	13.36	38	14238	335494	50255354
Pleural effusion	21.58	13.36	61	14215	81393	50509455
Hepatitis cholestatic	21.37	13.36	16	14260	6101	50584747
Haemolytic anaemia	21.27	13.36	19	14257	9273	50581575
Joint swelling	20.94	13.36	23	14253	245263	50345585
Bradycardia	20.88	13.36	52	14224	64374	50526474
Generalised tonic-clonic seizure	20.76	13.36	31	14245	26279	50564569
Acute kidney injury	20.52	13.36	122	14154	227936	50362912
Altered state of consciousness	20.50	13.36	28	14248	21882	50568966
Swelling	20.49	13.36	16	14260	200856	50389992
Vestibular disorder	20.38	13.36	9	14267	1260	50589588
Face oedema	20.12	13.36	25	14251	17814	50573034
Clostridium difficile infection	20.11	13.36	30	14246	25409	50565439
Wound	19.98	13.36	3	14273	105791	50485057
Therapeutic product effect decreased	19.50	13.36	7	14269	136043	50454805
Eosinophilic pneumonia acute	19.46	13.36	6	14270	304	50590544
Shock haemorrhagic	18.97	13.36	17	14259	8327	50582521
Drug reaction with eosinophilia and systemic symptoms	18.96	13.36	31	14245	28393	50562455
Post procedural haemorrhage	18.93	13.36	16	14260	7254	50583594
Laryngeal dyspnoea	18.77	13.36	5	14271	149	50590699
Shock	18.73	13.36	26	14250	20624	50570224
Hypokalaemia	18.71	13.36	61	14215	87931	50502917
Abdominal wound dehiscence	18.52	13.36	5	14271	157	50590691
Pyomyositis	18.40	13.36	6	14270	365	50590483
Spinal cord haematoma	18.23	13.36	5	14271	167	50590681
Oligohydramnios	17.80	13.36	14	14262	5736	50585112
Manipulation	17.75	13.36	4	14272	58	50590790
Hypoventilation	17.72	13.36	12	14264	3909	50586939
Procedural complication	17.71	13.36	13	14263	4810	50586038
Asthenia	17.65	13.36	40	14236	319002	50271846
Oxygen saturation decreased	17.62	13.36	53	14223	73195	50517653
Mycobacterial peritonitis	17.56	13.36	4	14272	61	50590787
Pain	17.56	13.36	94	14182	578809	50012039
Emotional distress	17.44	13.36	30	14246	28633	50562215
Linear IgA disease	17.30	13.36	8	14268	1246	50589602
Injection site pain	17.17	13.36	5	14271	111019	50479829
Clostridium difficile colitis	17.09	13.36	23	14253	17719	50573129
Arthralgia	17.03	13.36	65	14211	438637	50152211
Toxicity to various agents	16.97	13.36	21	14255	212478	50378370
Treatment failure	16.70	13.36	9	14267	137628	50453220
Nasopharyngitis	16.56	13.36	18	14258	192909	50397939
Peritoneal cloudy effluent	16.35	13.36	4	14272	84	50590764
Angioedema	16.18	13.36	34	14242	37642	50553206
Jaundice acholuric	15.97	13.36	4	14272	93	50590755
Keratitis fungal	15.89	13.36	4	14272	95	50590753
Deep vein thrombosis	15.75	13.36	51	14225	73253	50517595
Renal vein thrombosis	15.43	13.36	5	14271	298	50590550
Decorticate posture	15.43	13.36	5	14271	298	50590550
Low birth weight baby	15.43	13.36	13	14263	5868	50584980
Insomnia	15.35	13.36	16	14260	174849	50415999
Irregular breathing	15.23	13.36	5	14271	311	50590537
Alanine aminotransferase increased	15.11	13.36	57	14219	88302	50502546
Cerebral infarction	15.00	13.36	24	14252	21580	50569268
Dizziness	14.98	13.36	49	14227	346320	50244528
Circulatory collapse	14.97	13.36	23	14253	19977	50570871
Arthrofibrosis	14.94	13.36	3	14273	24	50590824
Foetal growth abnormality	14.94	13.36	3	14273	24	50590824
Cholestasis	14.69	13.36	26	14250	25375	50565473
Blood immunoglobulin A decreased	14.53	13.36	5	14271	359	50590489
Serratia test positive	14.43	13.36	3	14273	29	50590819
Septic shock	14.35	13.36	42	14234	57133	50533715
Infusion related reaction	14.35	13.36	16	14260	169541	50421307
Hypoxia	14.24	13.36	39	14237	51084	50539764
Bradycardia foetal	14.18	13.36	5	14271	386	50590462
Multiple lentigines syndrome	14.03	13.36	4	14272	154	50590694
Normal newborn	13.98	13.36	13	14263	6678	50584170
Renal impairment	13.94	13.36	50	14226	75611	50515237
Anaemia	13.91	13.36	120	14156	252336	50338512
Aspartate aminotransferase increased	13.91	13.36	51	14225	77947	50512901
Haemodynamic instability	13.78	13.36	14	14262	8010	50582838
Cholelithiasis	13.75	13.36	32	14244	37941	50552907
Pulseless electrical activity	13.73	13.36	13	14263	6828	50584020
Weight decreased	13.69	13.36	26	14250	221219	50369629
Atelectasis	13.66	13.36	21	14255	18249	50572599
Chest expansion decreased	13.54	13.36	3	14273	40	50590808
Brain oedema	13.41	13.36	17	14259	12353	50578495

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	294.26	14.79	133	12313	13203	29548878
Anaphylactic reaction	220.91	14.79	140	12306	27433	29534648
Hypoprothrombinaemia	148.79	14.79	34	12412	342	29561739
Fear	98.55	14.79	57	12389	9447	29552634
Kounis syndrome	88.09	14.79	32	12414	1797	29560284
Renal injury	77.13	14.79	50	12396	10152	29551929
Anhedonia	74.16	14.79	43	12403	7157	29554924
Injury	72.97	14.79	62	12384	18984	29543097
Hypotension	69.53	14.79	209	12237	194145	29367936
Acute generalised exanthematous pustulosis	67.40	14.79	37	12409	5546	29556535
Drug reaction with eosinophilia and systemic symptoms	66.66	14.79	70	12376	27922	29534159
Emotional distress	63.23	14.79	50	12396	13845	29548236
Fatigue	54.66	14.79	33	12413	316788	29245293
Vitamin K deficiency	54.42	14.79	14	12432	239	29561842
Hypovitaminosis	53.84	14.79	16	12430	474	29561607
Urticaria	49.26	14.79	85	12361	54575	29507506
Unevaluable event	43.37	14.79	58	12388	29793	29532288
Post procedural complication	42.21	14.79	35	12411	10354	29551727
Erythema	40.90	14.79	95	12351	75511	29486570
Vitamin K decreased	38.94	14.79	8	12438	46	29562035
Post procedural hypotension	37.58	14.79	8	12438	56	29562025
Shock	36.45	14.79	45	12401	21359	29540722
Blood pressure decreased	36.18	14.79	67	12379	45410	29516671
Death	35.40	14.79	56	12390	342028	29220053
Bronchospasm	34.19	14.79	30	12416	9579	29552502
Stress	33.13	14.79	43	12403	21447	29540634
Rash	32.70	14.79	162	12284	189657	29372424
Dizziness	32.29	14.79	20	12426	189664	29372417
Adrenal suppression	32.07	14.79	11	12435	521	29561560
Hyperthermia malignant	30.68	14.79	15	12431	1769	29560312
Metabolic acidosis	30.60	14.79	56	12390	37606	29524475
Post procedural haematoma	30.56	14.79	14	12432	1427	29560654
Multiple organ dysfunction syndrome	30.56	14.79	76	12370	63040	29499041
Rash maculo-papular	30.49	14.79	44	12402	24245	29537836
Jaundice cholestatic	30.19	14.79	20	12426	4206	29557875
Renal impairment	29.44	14.79	88	12358	81245	29480836
Gastritis fungal	29.42	14.79	7	12439	85	29561996
Weight decreased	28.44	14.79	14	12432	150891	29411190
Tubulointerstitial nephritis	28.29	14.79	36	12410	17607	29544474
Brain herniation	27.93	14.79	18	12428	3615	29558466
Clostridium difficile colitis	27.86	14.79	31	12415	13181	29548900
Coagulation factor X level decreased	27.20	14.79	5	12441	14	29562067
Ventricular tachycardia	27.04	14.79	40	12406	22534	29539547
Renal failure	26.19	14.79	109	12337	118490	29443591
Pericarditis fungal	25.58	14.79	7	12439	153	29561928
Serotonin syndrome	25.38	14.79	34	12412	17478	29544603
Thymus hypoplasia	25.28	14.79	7	12439	160	29561921
Lymphoid tissue hypoplasia	25.28	14.79	7	12439	160	29561921
Coagulopathy	24.79	14.79	34	12412	17873	29544208
Linear IgA disease	24.21	14.79	12	12434	1457	29560624
Hepatic function abnormal	24.19	14.79	52	12394	39207	29522874
Meningitis fungal	23.69	14.79	6	12440	96	29561985
Pseudomonal sepsis	23.66	14.79	15	12431	2927	29559154
Toxic epidermal necrolysis	22.95	14.79	33	12413	18120	29543961
Conjunctival ulcer	22.38	14.79	5	12441	45	29562036
Anaesthetic complication	22.24	14.79	10	12436	976	29561105
Device related infection	22.12	14.79	30	12416	15606	29546475
Burkholderia test positive	22.12	14.79	10	12436	989	29561092
Type I hypersensitivity	21.44	14.79	10	12436	1062	29561019
Spontaneous haematoma	21.37	14.79	8	12438	489	29561592
Drug-induced liver injury	21.24	14.79	35	12411	21620	29540461
Intrapericardial thrombosis	21.23	14.79	5	12441	58	29562023
Myoclonus	21.09	14.79	27	12419	13282	29548799
Drug hypersensitivity	21.06	14.79	70	12376	68336	29493745
Post embolisation syndrome	20.77	14.79	5	12441	64	29562017
Malaise	20.69	14.79	22	12424	159580	29402501
Factor V inhibition	20.55	14.79	6	12440	167	29561914
Drug eruption	20.53	14.79	30	12416	16711	29545370
Pyrexia	20.23	14.79	197	12249	287425	29274656
Tachycardia	19.59	14.79	71	12375	72339	29489742
Kidney transplant rejection	19.36	14.79	19	12427	6986	29555095
Dysbiosis	19.30	14.79	7	12439	391	29561690
Toxicity to various agents	19.28	14.79	27	12419	173634	29388447
Disseminated aspergillosis	18.92	14.79	7	12439	414	29561667
Viral uveitis	18.43	14.79	4	12442	31	29562050
Post procedural haemorrhage	18.29	14.79	19	12427	7472	29554609
Systemic mastocytosis	18.20	14.79	5	12441	111	29561970
Cardiac valve vegetation	18.18	14.79	7	12439	462	29561619
Coagulation factor VII level decreased	17.83	14.79	5	12441	120	29561961
Shock haemorrhagic	17.75	14.79	21	12425	9530	29552551
Eyelid oedema	17.55	14.79	15	12431	4621	29557460
Headache	17.45	14.79	29	12417	173978	29388103
Appendicitis perforated	17.08	14.79	10	12436	1693	29560388
Pathogen resistance	17.03	14.79	19	12427	8097	29553984
Drug chemical incompatibility	17.03	14.79	3	12443	6	29562075
Arteritis	16.99	14.79	6	12440	310	29561771
Procedural hypotension	16.87	14.79	8	12438	882	29561199
Blood creatine phosphokinase MB increased	16.79	14.79	10	12436	1747	29560334
Nodal rhythm	16.62	14.79	9	12437	1311	29560770
Product dose omission issue	16.60	14.79	10	12436	96373	29465708
Haemolytic anaemia	16.35	14.79	20	12426	9399	29552682
Laryngeal oedema	16.12	14.79	12	12434	3036	29559045
Cardiac arrest	16.09	14.79	75	12371	85516	29476565
Angioedema	16.03	14.79	39	12407	31876	29530205
Toxic shock syndrome	15.96	14.79	6	12440	371	29561710
Electrocardiogram ST segment elevation	15.93	14.79	14	12432	4478	29557603
Acinetobacter infection	15.82	14.79	8	12438	1014	29561067
Asthenia	15.64	14.79	43	12403	215207	29346874
Prothrombin level decreased	15.56	14.79	8	12438	1050	29561031
Pseudomembranous colitis	15.50	14.79	11	12435	2586	29559495
Arthrofibrosis	15.40	14.79	4	12442	71	29562010
Diarrhoea	15.38	14.79	80	12366	332618	29229463
Disseminated intravascular coagulation	15.33	14.79	29	12417	19951	29542130
Delayed recovery from anaesthesia	15.26	14.79	7	12439	716	29561365
Pruritus	14.88	14.79	92	12354	116757	29445324
Reperfusion injury	14.86	14.79	4	12442	82	29561999

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	687.26	12.61	300	24529	30028	64443875
Anaphylactic reaction	392.08	12.61	273	24556	68391	64405512
Hypotension	194.05	12.61	442	24387	380532	64093371
Hypoprothrombinaemia	179.34	12.61	44	24785	675	64473228
Acute generalised exanthematous pustulosis	165.76	12.61	89	24740	13969	64459934
Kounis syndrome	128.01	12.61	47	24782	2978	64470925
Fear	116.81	12.61	81	24748	20090	64453813
Vitamin K deficiency	107.84	12.61	29	24800	650	64473253
Urticaria	106.68	12.61	198	24631	147119	64326784
Fatigue	106.57	12.61	80	24749	748650	63725253
Arthrodesis	105.88	12.61	37	24792	2030	64471873
Renal injury	103.79	12.61	68	24761	15361	64458542
Anhedonia	98.58	12.61	63	24766	13643	64460260
Bronchospasm	95.92	12.61	74	24755	21608	64452295
Erythema	87.15	12.61	210	24619	186860	64287043
Drug-induced liver injury	81.37	12.61	96	24733	47547	64426356
Unevaluable event	80.11	12.61	98	24731	50391	64423512
Injury	79.80	12.61	103	24726	55889	64418014
Drug reaction with eosinophilia and systemic symptoms	76.11	12.61	99	24730	54118	64419785
Rash	70.20	12.61	355	24474	458194	64015709
Renal failure	69.11	12.61	189	24640	181499	64292404
Blood pressure decreased	67.59	12.61	120	24709	86079	64387824
Type I hypersensitivity	66.96	12.61	31	24798	3543	64470360
Emotional distress	63.83	12.61	74	24755	35964	64437939
Post procedural complication	63.60	12.61	58	24771	21295	64452608
Tachycardia	56.26	12.61	155	24674	149424	64324479
Drug hypersensitivity	53.70	12.61	207	24622	237608	64236295
Anaesthetic complication	53.45	12.61	24	24805	2555	64471348
Cardiac arrest	51.48	12.61	153	24676	153911	64319992
Toxic epidermal necrolysis	50.81	12.61	67	24762	37099	64436804
Hypovitaminosis	49.76	12.61	17	24812	871	64473032
Headache	49.31	12.61	80	24749	529387	63944516
Shock	49.31	12.61	67	24762	38173	64435730
Coagulopathy	49.07	12.61	61	24768	31859	64442044
Clostridium difficile colitis	48.37	12.61	56	24773	27167	64446736
Toxicity to various agents	46.39	12.61	43	24786	363470	64110433
Multiple organ dysfunction syndrome	45.19	12.61	112	24717	101301	64372602
Dizziness	43.90	12.61	61	24768	430102	64043801
Hepatic function abnormal	43.45	12.61	84	24745	64229	64409674
Vascular purpura	41.23	12.61	20	24809	2536	64471367
Death	41.22	12.61	77	24752	482628	63991275
Malaise	40.61	12.61	56	24773	396191	64077712
Renal impairment	40.36	12.61	129	24700	134888	64339015
Post procedural haematoma	40.17	12.61	19	24810	2279	64471624
Linear IgA disease	39.68	12.61	20	24809	2754	64471149
Product dose omission issue	39.27	12.61	13	24816	194734	64279169
Disseminated intravascular coagulation	39.19	12.61	55	24774	32293	64441610
Joint swelling	39.06	12.61	17	24812	215365	64258538
Hyperthermia malignant	38.94	12.61	19	24810	2440	64471463
Pseudomembranous colitis	38.87	12.61	24	24805	4892	64469011
Weight increased	38.44	12.61	17	24812	213331	64260572
Tubulointerstitial nephritis	38.11	12.61	53	24776	30856	64443047
Lymphoid tissue hypoplasia	38.00	12.61	12	24817	479	64473424
Post procedural hypotension	37.35	12.61	8	24821	64	64473839
Vitamin K decreased	37.13	12.61	8	24821	66	64473837
Thymus hypoplasia	37.03	12.61	12	24817	521	64473382
Peripheral swelling	35.63	12.61	18	24811	209135	64264768
Weight decreased	35.03	12.61	35	24794	285704	64188199
Sinusitis	34.65	12.61	7	24822	145921	64327982
Disseminated aspergillosis	34.38	12.61	12	24817	656	64473247
Recurrence of neuromuscular blockade	33.75	12.61	9	24820	195	64473708
Rash maculo-papular	33.71	12.61	63	24766	46963	64426940
Haemolytic anaemia	33.64	12.61	36	24793	16017	64457886
Pain in extremity	32.91	12.61	41	24788	303044	64170859
Ventricular tachycardia	32.55	12.61	52	24777	34213	64439690
Shock haemorrhagic	32.30	12.61	36	24793	16755	64457148
Arthralgia	31.54	12.61	78	24751	442182	64031721
Toxic skin eruption	31.49	12.61	38	24791	19246	64454657
Pseudomonal sepsis	30.47	12.61	21	24808	5151	64468752
Alopecia	30.16	12.61	13	24816	165677	64308226
Post procedural haemorrhage	29.87	12.61	30	24799	12401	64461502
Device related infection	29.81	12.61	47	24782	30579	64443324
Injection site pain	29.43	12.61	4	24825	111404	64362499
Diarrhoea	29.43	12.61	161	24668	722543	63751360
Drug intolerance	29.38	12.61	18	24811	187974	64285929
Angioedema	29.36	12.61	70	24759	61751	64412152
Shoulder arthroplasty	28.74	12.61	16	24813	2693	64471210
Asthenia	28.59	12.61	78	24751	427966	64045937
Arthrofibrosis	28.31	12.61	7	24822	111	64473792
Brain herniation	28.24	12.61	22	24807	6511	64467392
Hepatic enzyme abnormal	28.18	12.61	21	24808	5818	64468085
Procedural hypotension	28.16	12.61	14	24815	1872	64472031
Dysbiosis	27.45	12.61	11	24818	884	64473019
Heparin-induced thrombocytopenia	27.16	12.61	24	24805	8455	64465448
Face oedema	26.92	12.61	40	24789	24721	64449182
Staphylococcal bacteraemia	26.75	12.61	26	24803	10329	64463574
Pyrexia	26.63	12.61	330	24499	558314	63915589
Conjunctival ulcer	26.55	12.61	6	24823	63	64473840
Nasopharyngitis	26.42	12.61	22	24807	196051	64277852
Fall	26.33	12.61	78	24751	416748	64057155
Tarsal tunnel syndrome	25.71	12.61	9	24820	496	64473407
Purpura senile	25.61	12.61	9	24820	502	64473401
Limb operation	25.51	12.61	15	24814	2799	64471104
Pericarditis fungal	25.49	12.61	7	24822	170	64473733
Metabolic acidosis	25.14	12.61	72	24757	70886	64403017
Gastritis fungal	24.90	12.61	7	24822	186	64473717
Tonic clonic movements	24.58	12.61	13	24816	1976	64471927
Laryngeal oedema	24.53	12.61	21	24808	7092	64466811
Drug eruption	24.16	12.61	47	24782	36089	64437814
Acute hepatic failure	23.95	12.61	39	24790	26073	64447830
Adrenal suppression	23.28	12.61	11	24818	1316	64472587
Bradycardia	22.74	12.61	98	24731	118121	64355782
Off label use	22.54	12.61	147	24682	632659	63841244
Insomnia	22.27	12.61	26	24803	197810	64276093
Acinetobacter infection	22.16	12.61	13	24816	2416	64471487
Pruritus	22.12	12.61	200	24629	312200	64161703
Clostridium difficile infection	21.74	12.61	45	24784	36118	64437785
Intrapericardial thrombosis	21.67	12.61	5	24824	58	64473845
Brain oedema	21.65	12.61	34	24795	22041	64451862
Oropharyngeal pain	21.64	12.61	4	24825	88863	64385040
Pyomyositis	21.41	12.61	8	24821	532	64473371
Thrombotic microangiopathy	21.19	12.61	29	24800	16626	64457277
Airway peak pressure increased	21.05	12.61	7	24822	330	64473573
Jaundice cholestatic	20.97	12.61	21	24808	8649	64465254
Post embolisation syndrome	20.74	12.61	5	24824	71	64473832
Meningitis fungal	20.71	12.61	6	24823	178	64473725
Pulseless electrical activity	20.63	12.61	25	24804	12714	64461189
Haemodynamic instability	20.55	12.61	27	24802	14885	64459018
Skin graft	20.40	12.61	9	24820	919	64472984
Manipulation	20.24	12.61	5	24824	79	64473824
Electrocardiogram ST segment elevation	20.22	12.61	19	24810	7240	64466663
Macular oedema	20.19	12.61	16	24813	4851	64469052
Eosinophilia	20.15	12.61	45	24784	38031	64435872
Intentional product use issue	19.86	12.61	6	24823	95358	64378545
Coagulation factor X level decreased	19.52	12.61	5	24824	92	64473811
Kidney transplant rejection	19.35	12.61	21	24808	9490	64464413
Musculoskeletal pain	19.08	12.61	4	24825	81290	64392613
Delayed recovery from anaesthesia	18.92	12.61	10	24819	1518	64472385
Tryptase increased	18.89	12.61	7	24822	455	64473448
Cytomegalovirus viraemia	18.77	12.61	22	24807	10806	64463097
Muscle spasms	18.77	12.61	16	24813	141007	64332896
Blood creatine phosphokinase MB increased	18.72	12.61	12	24817	2609	64471294
Myoclonus	18.43	12.61	34	24795	25084	64448819
Resorption bone increased	18.42	12.61	9	24820	1159	64472744
Intentional product misuse	18.16	12.61	3	24826	72292	64401611
Eyelid oedema	18.13	12.61	23	24806	12256	64461647
Respiratory failure	18.06	12.61	115	24714	161068	64312835
Gastrointestinal disorder	18.05	12.61	6	24823	89703	64384200
Circulatory collapse	18.00	12.61	40	24789	33692	64440211
Balance disorder	17.99	12.61	5	24824	83921	64389982
Gait disturbance	17.93	12.61	24	24805	172131	64301772
Postoperative wound infection	17.92	12.61	21	24808	10315	64463588
Procedural haemorrhage	17.69	12.61	14	24815	4238	64469665
Contusion	17.68	12.61	11	24818	113954	64359949
Spinal cord haematoma	17.66	12.61	6	24823	302	64473601
Premature delivery	17.36	12.61	28	24801	18561	64455342
Fear of death	17.33	12.61	9	24820	1318	64472585
Stress	17.31	12.61	57	24772	60477	64413426
Hypoventilation	17.27	12.61	16	24813	5990	64467913
Delayed graft function	17.12	12.61	12	24817	3024	64470879
Implant site haematoma	16.98	12.61	5	24824	157	64473746
Dyspnoea	16.98	12.61	186	24643	718488	63755415
Diabetes insipidus	16.93	12.61	14	24815	4507	64469396
Factor V inhibition	16.80	12.61	6	24823	351	64473552
Procedural pain	16.78	12.61	25	24804	15483	64458420
Feeling abnormal	16.77	12.61	16	24813	133586	64340317
Hepatitis cholestatic	16.74	12.61	22	24807	12133	64461770
Procedural complication	16.48	12.61	17	24812	7248	64466655
Septic shock	16.29	12.61	82	24747	105355	64368548
Pathogen resistance	16.20	12.61	22	24807	12521	64461382
Infusion related reaction	16.06	12.61	24	24805	164443	64309460
Drug chemical incompatibility	15.97	12.61	4	24825	67	64473836
Mycobacterial peritonitis	15.97	12.61	4	24825	67	64473836
Systemic lupus erythematosus	15.95	12.61	5	24824	77607	64396296
Coagulation factor VII level decreased	15.73	12.61	5	24824	204	64473699
Irregular breathing	15.70	12.61	6	24823	425	64473478
Staphylococcal infection	15.65	12.61	49	24780	50629	64423274
Herpes simplex hepatitis	15.51	12.61	6	24823	439	64473464
Mobility decreased	15.19	12.61	7	24822	85833	64388070
Vestibular disorder	15.16	12.61	10	24819	2283	64471620
Asthma	15.03	12.61	9	24820	95216	64378687
Lower respiratory tract infection	14.86	12.61	9	24820	94605	64379298
Spontaneous haematoma	14.85	12.61	8	24821	1263	64472640
Cardiac valve vegetation	14.75	12.61	7	24822	846	64473057
Encephalopathy	14.74	12.61	53	24776	58766	64415137
Wound infection	14.73	12.61	23	24806	14841	64459062
Catheter site haemorrhage	14.71	12.61	13	24816	4578	64469325
Myalgia	14.68	12.61	24	24805	158593	64315310
Laryngeal dyspnoea	14.60	12.61	5	24824	258	64473645
Disease progression	14.50	12.61	20	24809	141660	64332243
Toxic shock syndrome	14.49	12.61	7	24822	879	64473024
Cataract subcapsular	14.47	12.61	7	24822	882	64473021
Maternal exposure during delivery	14.46	12.61	7	24822	883	64473020
Systemic mastocytosis	14.26	12.61	5	24824	277	64473626
Altered state of consciousness	13.95	12.61	39	24790	37863	64436040
Hypoxia	13.93	12.61	69	24760	88080	64385823
Clostridium test positive	13.89	12.61	12	24817	4103	64469800
Hypersensitivity vasculitis	13.88	12.61	15	24814	6746	64467157
Jaundice acholuric	13.79	12.61	4	24825	119	64473784
Injection site erythema	13.79	12.61	5	24824	70795	64403108
Aspartate aminotransferase increased	13.75	12.61	86	24743	119702	64354201
Propionibacterium infection	13.73	12.61	5	24824	309	64473594
Decorticate posture	13.69	12.61	5	24824	312	64473591
Memory impairment	13.66	12.61	8	24821	85674	64388229
Vertigo	13.65	12.61	3	24826	59008	64414895
Syncope	13.54	12.61	25	24804	157610	64316293
Stupor	13.47	12.61	14	24815	6021	64467882
Arterial angioplasty	13.41	12.61	3	24826	30	64473873
Appendicitis perforated	13.29	12.61	10	24819	2810	64471093
Cellulitis	13.19	12.61	71	24758	93586	64380317
Exposure during pregnancy	13.14	12.61	62	24767	77613	64396290
Serotonin syndrome	13.08	12.61	39	24790	39243	64434660
Platelet dysfunction	13.00	12.61	5	24824	360	64473543
Respiratory distress	12.98	12.61	47	24782	52284	64421619
Necrotising oesophagitis	12.97	12.61	6	24823	684	64473219
Cough	12.97	12.61	66	24763	302082	64171821
Migraine	12.95	12.61	4	24825	62673	64411230
Serratia test positive	12.93	12.61	4	24825	149	64473754
Myocardial infarction	12.79	12.61	28	24801	165793	64308110
Arteriospasm coronary	12.78	12.61	13	24816	5452	64468451
Endotracheal intubation complication	12.76	12.61	6	24823	710	64473193
Renal tubular necrosis	12.69	12.61	27	24802	22083	64451820
Arteritis	12.66	12.61	6	24823	722	64473181

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DB04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Pneumonia due to Streptococcus	indication	34020007
Lower respiratory tract infection	indication	50417007
Bacterial pneumonia	indication	53084003	DOID:874
Cholangitis	indication	82403002	DOID:9446
Infection of bone	indication	111253001
Bacterial endocarditis	indication	301183007
Bacterial urinary infection	indication	312124009
Infectious disorder of joint	indication	363162000
Genitourinary Tract Infections	indication
Prevention of Perioperative Infection	indication
Prevention of Bacterial Endocarditis	off-label use
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.22	acidic
pKa2	12.21	acidic
pKa3	1.52	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE					WOMBAT-PK

External reference:

ID	Source
4019659	VUID
N0000147751	NUI
D00905	KEGG_DRUG
27164-46-1	SECONDARY_CAS_RN
203171	RXNORM
4017460	VANDF
4019659	VANDF
C0007546	UMLSCUI
CHEBI:474053	CHEBI
CHEMBL1435	ChEMBL_ID
CHEMBL1200523	ChEMBL_ID
D002437	MESH_DESCRIPTOR_UI
DB01327	DRUGBANK_ID
10935	IUPHAR_LIGAND_ID
2991	INN_ID
IHS69L0Y4T	UNII
33255	PUBCHEM_CID
35509	MMSL
4371	MMSL
948	MMSL
d00007	MMSL
002720	NDDF
004841	NDDF
387470007	SNOMEDCT_US
80972005	SNOMEDCT_US
81088002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9261	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	23 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9262	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9262	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9665	INJECTION, POWDER, FOR SOLUTION	20 g	INTRAVENOUS	ANDA	23 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9923	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9923	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9924	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9924	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9983	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	23 sections
Cefazolin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3103	SOLUTION	1 g	INTRAVENOUS	NDA	27 sections
Cefazolin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3105	SOLUTION	2 g	INTRAVENOUS	NDA	27 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3503	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3503	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3508	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	26 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9833	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	14 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9834	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	10 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9835	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	11 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2585	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	23 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3450	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	21 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3451	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	21 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3452	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	21 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-100	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-100	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-101	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-101	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-102	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-102	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	44567-120	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	21 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	44567-706	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	21 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	44567-707	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	21 sections